vs
伯乐实验室（BIO）与LifeStance Health Group, Inc.（LFST）财务数据对比。点击上方公司名可切换其他公司
伯乐实验室的季度营收约是LifeStance Health Group, Inc.的1.8倍（$693.2M vs $382.2M），伯乐实验室净利率更高（103.9% vs 3.1%，领先100.8%），LifeStance Health Group, Inc.同比增速更快（17.4% vs 3.9%），伯乐实验室自由现金流更多（$119.1M vs $46.6M），过去两年LifeStance Health Group, Inc.的营收复合增速更高（12.8% vs 6.5%）
美国伯乐实验室是深耕生命科学研究与临床诊断领域的专业技术产品开发商及制造商，1952年由加州大学伯克利分校校友施瓦茨夫妇在伯克利创立，总部位于加州赫拉克勒斯，业务网络覆盖全球。
LifeStance Health Group是美国的门诊行为健康服务提供商，支持线下面诊与远程诊疗两种服务模式，业务涵盖心理咨询、精神科诊疗、经颅磁刺激（TMS）以及氯胺酮治疗等。该公司曾多次因劳动违规、客户信息泄露及误导投资者相关问题遭遇诉讼。
BIO vs LFST — 直观对比
营收规模更大
BIO
是对方的1.8倍
$382.2M
营收增速更快
LFST
高出13.6%
3.9%
净利率更高
BIO
高出100.8%
3.1%
自由现金流更多
BIO
多$72.5M
$46.6M
两年增速更快
LFST
近两年复合增速
6.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $693.2M | $382.2M |
| 净利润 | $720.0M | $11.7M |
| 毛利率 | 49.8% | — |
| 营业利润率 | -17.2% | 4.7% |
| 净利率 | 103.9% | 3.1% |
| 营收同比 | 3.9% | 17.4% |
| 净利润同比 | 200.6% | 264.1% |
| 每股收益（稀释后） | $26.59 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIOLFST
| Q4 25 | $693.2M | $382.2M | ||
| Q3 25 | $653.0M | $363.8M | ||
| Q2 25 | $651.6M | $345.3M | ||
| Q1 25 | $585.4M | $333.0M | ||
| Q4 24 | $667.5M | $325.5M | ||
| Q3 24 | $649.7M | $312.7M | ||
| Q2 24 | $638.5M | $312.3M | ||
| Q1 24 | $610.8M | $300.4M |
净利润BIOLFST
| Q4 25 | $720.0M | $11.7M | ||
| Q3 25 | $-341.9M | $1.1M | ||
| Q2 25 | $317.8M | $-3.8M | ||
| Q1 25 | $64.0M | $709.0K | ||
| Q4 24 | $-715.8M | $-7.1M | ||
| Q3 24 | $653.2M | $-6.0M | ||
| Q2 24 | $-2.2B | $-23.3M | ||
| Q1 24 | $383.9M | $-21.1M |
毛利率BIOLFST
| Q4 25 | 49.8% | — | ||
| Q3 25 | 52.6% | — | ||
| Q2 25 | 53.0% | — | ||
| Q1 25 | 52.3% | — | ||
| Q4 24 | 51.2% | — | ||
| Q3 24 | 54.8% | — | ||
| Q2 24 | 55.6% | — | ||
| Q1 24 | 53.4% | — |
营业利润率BIOLFST
| Q4 25 | -17.2% | 4.7% | ||
| Q3 25 | 10.0% | 2.0% | ||
| Q2 25 | 11.8% | -0.9% | ||
| Q1 25 | 4.0% | 0.5% | ||
| Q4 24 | 8.7% | 0.3% | ||
| Q3 24 | 9.9% | 0.0% | ||
| Q2 24 | 15.9% | -5.1% | ||
| Q1 24 | 7.3% | -5.6% |
净利率BIOLFST
| Q4 25 | 103.9% | 3.1% | ||
| Q3 25 | -52.4% | 0.3% | ||
| Q2 25 | 48.8% | -1.1% | ||
| Q1 25 | 10.9% | 0.2% | ||
| Q4 24 | -107.2% | -2.2% | ||
| Q3 24 | 100.5% | -1.9% | ||
| Q2 24 | -339.2% | -7.5% | ||
| Q1 24 | 62.9% | -7.0% |
每股收益（稀释后）BIOLFST
| Q4 25 | $26.59 | — | ||
| Q3 25 | $-12.70 | — | ||
| Q2 25 | $11.67 | — | ||
| Q1 25 | $2.29 | — | ||
| Q4 24 | $-25.89 | — | ||
| Q3 24 | $23.34 | — | ||
| Q2 24 | $-76.26 | — | ||
| Q1 24 | $13.45 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.5B | $248.6M |
| 总债务越低越好 | $1.2B | $282.8M |
| 股东权益账面价值 | $7.5B | $1.5B |
| 总资产 | $10.6B | $2.2B |
| 负债/权益比越低杠杆越低 | 0.16× | 0.19× |
8季度趋势，按日历期对齐
现金及短期投资BIOLFST
| Q4 25 | $1.5B | $248.6M | ||
| Q3 25 | $1.4B | $203.9M | ||
| Q2 25 | $1.4B | $188.9M | ||
| Q1 25 | $1.7B | $134.3M | ||
| Q4 24 | $1.7B | $154.6M | ||
| Q3 24 | $1.6B | $102.6M | ||
| Q2 24 | $1.6B | $87.0M | ||
| Q1 24 | $1.6B | $49.5M |
总债务BIOLFST
| Q4 25 | $1.2B | $282.8M | ||
| Q3 25 | $1.2B | $284.6M | ||
| Q2 25 | — | $286.4M | ||
| Q1 25 | — | $288.2M | ||
| Q4 24 | $1.2B | $290.0M | ||
| Q3 24 | — | $287.3M | ||
| Q2 24 | — | $288.0M | ||
| Q1 24 | — | $288.8M |
股东权益BIOLFST
| Q4 25 | $7.5B | $1.5B | ||
| Q3 25 | $6.7B | $1.5B | ||
| Q2 25 | $7.1B | $1.5B | ||
| Q1 25 | $6.7B | $1.5B | ||
| Q4 24 | $6.6B | $1.4B | ||
| Q3 24 | $7.5B | $1.4B | ||
| Q2 24 | $6.8B | $1.4B | ||
| Q1 24 | $9.1B | $1.4B |
总资产BIOLFST
| Q4 25 | $10.6B | $2.2B | ||
| Q3 25 | $9.7B | $2.1B | ||
| Q2 25 | $10.2B | $2.1B | ||
| Q1 25 | $9.5B | $2.1B | ||
| Q4 24 | $9.4B | $2.1B | ||
| Q3 24 | $10.6B | $2.1B | ||
| Q2 24 | $9.7B | $2.1B | ||
| Q1 24 | $12.6B | $2.1B |
负债/权益比BIOLFST
| Q4 25 | 0.16× | 0.19× | ||
| Q3 25 | 0.18× | 0.19× | ||
| Q2 25 | — | 0.19× | ||
| Q1 25 | — | 0.20× | ||
| Q4 24 | 0.18× | 0.20× | ||
| Q3 24 | — | 0.20× | ||
| Q2 24 | — | 0.20× | ||
| Q1 24 | — | 0.20× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $164.9M | $57.6M |
| 自由现金流经营现金流 - 资本支出 | $119.1M | $46.6M |
| 自由现金流率自由现金流/营收 | 17.2% | 12.2% |
| 资本支出强度资本支出/营收 | 6.6% | 2.9% |
| 现金转化率经营现金流/净利润 | 0.23× | 4.93× |
| 过去12个月自由现金流最近4个季度 | $374.6M | $110.0M |
8季度趋势，按日历期对齐
经营现金流BIOLFST
| Q4 25 | $164.9M | $57.6M | ||
| Q3 25 | $120.9M | $27.3M | ||
| Q2 25 | $116.5M | $64.4M | ||
| Q1 25 | $129.9M | $-3.1M | ||
| Q4 24 | $124.2M | $62.3M | ||
| Q3 24 | $163.6M | $22.7M | ||
| Q2 24 | $97.6M | $44.1M | ||
| Q1 24 | $69.8M | $-21.8M |
自由现金流BIOLFST
| Q4 25 | $119.1M | $46.6M | ||
| Q3 25 | $89.2M | $17.0M | ||
| Q2 25 | $70.8M | $56.6M | ||
| Q1 25 | $95.5M | $-10.3M | ||
| Q4 24 | $81.2M | $56.0M | ||
| Q3 24 | $123.4M | $17.7M | ||
| Q2 24 | $55.4M | $39.0M | ||
| Q1 24 | $29.6M | $-26.9M |
自由现金流率BIOLFST
| Q4 25 | 17.2% | 12.2% | ||
| Q3 25 | 13.7% | 4.7% | ||
| Q2 25 | 10.9% | 16.4% | ||
| Q1 25 | 16.3% | -3.1% | ||
| Q4 24 | 12.2% | 17.2% | ||
| Q3 24 | 19.0% | 5.7% | ||
| Q2 24 | 8.7% | 12.5% | ||
| Q1 24 | 4.8% | -9.0% |
资本支出强度BIOLFST
| Q4 25 | 6.6% | 2.9% | ||
| Q3 25 | 4.9% | 2.8% | ||
| Q2 25 | 7.0% | 2.2% | ||
| Q1 25 | 5.9% | 2.2% | ||
| Q4 24 | 6.4% | 1.9% | ||
| Q3 24 | 6.2% | 1.6% | ||
| Q2 24 | 6.6% | 1.6% | ||
| Q1 24 | 6.6% | 1.7% |
现金转化率BIOLFST
| Q4 25 | 0.23× | 4.93× | ||
| Q3 25 | — | 25.34× | ||
| Q2 25 | 0.37× | — | ||
| Q1 25 | 2.03× | -4.36× | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.25× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.18× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIO
| Clinical Diagnostics | $425.3M | 61% |
| Life Science | $267.9M | 39% |
LFST
暂无分部数据
